Tempus and Genialis Join Forces to Revolutionize Cancer Care

Tempus and Genialis Join Forces to Revolutionize Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence for advancing precision medicine, is excited to announce its collaboration with Genialis, a pioneer in RNA biomarkers. This partnership aims to leverage Tempus' extensive multimodal dataset to drive the development of innovative RNA-based algorithms across various cancer types.

The Need for Accurate Biomarkers in Cancer Treatment

For cancer patients, the journey often involves a maze of varied treatment options and limited effective guidance on what best suits their individual needs. A significant challenge facing oncologists is the lack of precise biomarkers that can reliably predict how different patients will respond to specific therapies. This limitation underscores the urgency for enhanced research and development in biomarker capabilities.

Genialis TM Supermodel: Paving the Way for Better Outcomes

Genialis has created an advanced AI foundation model that utilizes insights from approximately one million RNA-sequencing samples drawn from a diverse global patient population. This innovative model, known as the Genialis TM Supermodel, is pivotal for producing actionable biomarker algorithms that can aid biopharmaceutical companies in refining their therapeutic strategies. The collaboration with Tempus will enable Genialis to validate this model using comprehensive real-world data, ensuring that the developed algorithms hold true clinical relevance.

Accelerating Clinical Implementation

As part of this strategic alliance, Genialis will utilize Tempus’ analytics platform, Lens, which grants access to large sets of de-identified patient records. This extensive database is vital for validating Genialis’ molecular models and ensuring faster routes to market for clinical algorithms. In exchange, Tempus retains the potential to evaluate and possibly license these innovative biomarker algorithms developed by Genialis, integrating them into its xR platform.

Practical Applications: Gaining Insights for Patient Benefit

Tempus’ dataset has been instrumental in the successful launch of Genialis™ krasID. This groundbreaking algorithm identifies patients who are most likely to benefit from KRAS-targeted therapies. Highlighted during a prestigious drug development summit, Genialis krasID provides unique predictions regarding patient responses to these therapies across varying cancer types and specific genetic mutations, having been validated against Tempus’ real-world data.

Voices from Leadership

Kate Sasser, Ph.D., the Chief Scientific Officer at Tempus, expressed enthusiasm for the partnership, stating, "We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care." The anticipation extends further with the potential realization of multimodal algorithms, promising rapid advancements in patient-specific treatment methodologies.

Empowering Transformation in Cancer Therapy

Rafael Rosengarten, Ph.D., CEO of Genialis, echoed the vision of this collaboration, remarking, "Biomarkers have the potential to transform how cancer is diagnosed and treated. With this strategic agreement with Tempus, Genialis will have access to an unparalleled data resource to validate our cutting-edge patient classifiers." This synergy is poised to impact the landscape of cancer diagnostics, providing a brighter future for patients facing complex treatment choices.

About Tempus

Tempus is committed to advancing precision medicine through the application of AI in healthcare. With an extensive library of multimodal data, the company empowers healthcare providers with essential tools that enhance personalized patient care. By harnessing data, Tempus seeks to ensure that each patient has access to treatment insights derived from previous cases, paving the way for improved outcomes.

About Genialis

Genialis strives to create a healthcare landscape where optimal outcomes are accessible for patients and their communities. Specializing in clinically actionable biomarkers, the company focuses on utilizing the most diverse cancer datasets to inform treatment decisions for various therapeutic approaches. Partnered with leaders in pharmaceuticals and diagnostics, Genialis is striving to transform the healthcare experience through data-driven insights.

Frequently Asked Questions

What is the main goal of the Tempus and Genialis collaboration?

The main goal is to develop RNA-based biomarker algorithms to enhance cancer diagnostics and treatment diagnostics.

What is the significance of biomarkers in cancer therapy?

Biomarkers can predict patient responses to therapies, leading to more personalized treatment plans and improved outcomes.

How does Tempus support Genialis in this collaboration?

Tempus provides access to its extensive multimodal dataset and analytics platform, which is crucial for the validation of Genialis' algorithms.

What is Genialis™ krasID?

Genialis™ krasID is an algorithm that predicts patient responses to KRAS-targeted therapies, validated through Tempus' real-world data.

How will this partnership impact cancer care?

This partnership aims to integrate advanced AI and RNA biomarkers, significantly improving the precision of cancer treatment and outcomes for patients.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.